AEON Biopharma (NASDAQ:AEON) Research Coverage Started at Lake Street Capital

Lake Street Capital began coverage on shares of AEON Biopharma (NASDAQ:AEON) in a research report released on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $1.00 price objective on the stock.

Separately, Zacks Research upgraded shares of AEON Biopharma to a “hold” rating in a research report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $1.00.

AEON Biopharma Stock Performance

NASDAQ AEON opened at $0.29 on Thursday. The company has a market capitalization of $7.41 million, a P/E ratio of 1.63 and a beta of 0.61. AEON Biopharma has a one year low of $0.22 and a one year high of $1.45. The stock has a 50 day moving average price of $0.58 and a 200-day moving average price of $0.88.

Institutional Investors Weigh In On AEON Biopharma

An institutional investor recently raised its position in AEON Biopharma stock. Geode Capital Management LLC raised its stake in shares of AEON Biopharma, Inc. (NASDAQ:AEON) by 27.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,134 shares of the company’s stock after purchasing an additional 13,061 shares during the period. Geode Capital Management LLC owned 0.51% of AEON Biopharma worth $66,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 22.78% of the company’s stock.

About AEON Biopharma

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical?stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.